The Effect of Acclydine in Chronic Fatigue Syndrome
Author Information
Author(s): Gerard K. H. T., Bleijenberg Gijs, van der Meer Jos W. M.
Primary Institution: Radboud University Nijmegen Medical Centre
Hypothesis
Does Acclydine increase biologically active IGF1 levels and improve symptoms in chronic fatigue syndrome (CFS) patients?
Conclusion
The study found no benefit of Acclydine over placebo in treating chronic fatigue syndrome.
Supporting Evidence
- The study did not find significant differences in fatigue severity or functional impairment between the Acclydine and placebo groups.
- IGF1 and IGFBP3 levels were similar in CFS patients and healthy controls.
- The trial was designed to minimize bias through double-blinding.
- Acclydine treatment was well tolerated with no important side effects reported.
Takeaway
The study tested a supplement called Acclydine to see if it helps people with chronic fatigue syndrome feel better, but it didn't work any better than a sugar pill.
Methodology
A randomized, placebo-controlled, double-blind clinical trial was conducted with 57 CFS patients over 14 weeks.
Potential Biases
The study was double-blind, minimizing bias in outcome assessment.
Limitations
The sample size was relatively small, which may limit the generalizability of the findings.
Participant Demographics
57 adult patients with chronic fatigue syndrome, matched with healthy controls.
Statistical Information
P-Value
p = 0.70
Confidence Interval
95% CI −4.4 to +6.5
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website